Apeiron Research Center conducts translational biomedical research focused on autologous cellular and biologic therapies, including bone marrowderived, adipose-derived, and platelet-based products. Program activities include laboratory characterization of biologic materials, development and validation of standardized processing methods, preclinical safety studies, and ethically supervised clinical research evaluating safety and biologic function. A central program objective is the structured advancement of research findings toward regulatory-compliant autologous Good Manufacturing Practice (GMP) processes that may support future clinical trials and evidence-based therapeutic applications. The organization maintains comprehensive quality management systems to ensure reproducibility, patient protection, and alignment with applicable federal and state regulatory standards. Research results contribute to scientific knowledge.
Main program · fiscal year 2025
Apeiron Research Center conducts translational biomedical research focused on autologous cellular and biologic therapies, including bone marrowderived, adipose-derived, and platelet-based products. Program activities include laboratory characterization of biologic materials, development and validation of standardized processing methods, preclinical safety studies, and ethically supervised clinical… Read more
Apeiron Research Center conducts translational biomedical research focused on autologous cellular and biologic therapies, including bone marrowderived, adipose-derived, and platelet-based products. Program activities include laboratory characterization of biologic materials, development and validation of standardized processing methods, preclinical safety studies, and ethically supervised clinical research evaluating safety and biologic function. A central program objective is the structured advancement of research findings toward regulatory-compliant autologous Good Manufacturing Practice (GMP) processes that may support future clinical trials and evidence-based therapeutic applications. The organization maintains comprehensive quality management systems to ensure reproducibility, patient protection, and alignment with applicable federal and state regulatory standards. Research results contribute to scientific knowledge
$1,440,854 spent
Where each dollar went · fiscal year 2025
Of every dollar it spent, 96¢ went to programs, 4¢ to management and 0¢ to fundraising.
Programs $1,440,854
Management $65,451
Fundraising $0
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$4,811,542Fiscal year 2025
Expenses$1,506,305Fiscal year 2025
Total assets$4,554,544Fiscal year 2025
Total liabilities$1,249,307Fiscal year 2025
Fiscal year ending December2025
Revenue$4,811,542
Expenses$1,506,305
Net income$3,305,237
Net assets$3,305,237
Notable sources of revenue
Percent of total revenue
Contributions
$4,803,605
99.8%
Program services
$0
0.0%
Investment income
$6,447
0.1%
Other (net)
$1,490
0.0%
Assets / debt
Total assets
$4,554,544
Total liabilities
$1,249,307
Net assets
$3,305,237
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$0
Expenses$0
Net income$0
Net assets$0
Notable sources of revenue
Percent of total revenue
Contributions
$0
—
Program services
—
—
Investment income
—
—
Other (net)
$0
—
Assets / debt
Total assets
—
Total liabilities
—
Net assets
$0
Compensation
Not in our extract for this year.
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?